pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

PhRMA weighs former Republican lawmakers and Trump administration officials for CEO role

Aug 20, 2026·read at Endpoints ↗Neutral

PhRMA, the pharma lobbying group, has been searching for a new chief executive for over four months.

The search has focused on candidates with Republican backgrounds, including former members of Congress and officials who served in the Trump administration.

Industry sources say the group is evaluating a range of experience from Capitol Hill legislative work to executive leadership in government, but no final decision has been announced.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “A mix of former Republican lawmakers and Trump admin leaders are in the race to lead PhRMA”

read at Endpoints ↗
87 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 3h agoThree deaths in China shake trust in its speedy clinical trial systemEndpoints
  • 3h agoFDA rejects Osteal combo therapy to treat joint-implant infectionsEndpoints
  • 6h agoUsing gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study findsEndpoints
  • 6h agoTry first, evaluate later: How the FDA is approaching digital health devicesEndpoints
  • 6h agoLilly partners with Amplitude on vaccines; Otsuka scraps psychedelic trialEndpoints